Gemcitabine-Based Chemotherapy After Folfirinox In Advanced Pancreatic Cancer

Gemcitabine-based chemotherapy after FOLFIRINOX in advanced pancreatic cancer

Debate 10: What do we do after FOLFIRINOX? - Gemcitabine is Standard

SEQUENCE: nab-paclitaxel/gemcitabine with modified FOLFOX in pancreatic cancer

FOLFIRINOX, gemcitabine + paclitaxel to enhance surgery outcomes for locally advanced PC

NEPAFOX: adjuvant gemcitabine vs. FOLFIRINOX in resectable pancreatic cancer

The protein RRP9 promotes gemcitabine resistance in pancreatic cancer by activating the AKT pathway

AJE Video Bytes

Optimizing first line treatment in metastatic pancreatic cancer

Perioperative chemotherapy with mfolfirinox vs gemcitabine/nab-paclitaxel for resectable pancrea...

#ESMO21 Highlights on gemcitabine vs mFOLFIRINOX in resected pancreatic cancer: PRODIGE 24/CCTG PA6

European Society for Medical Oncology (ESMO)

Schedules for Gemcitabine, Nab-Paclitaxel for Pancreatic Cancer

Frontline Options for the Treatment of Pancreatic Cancer

Targeted Oncology

Dr. Weinberg Discusses the Use of FOLFIRINOX in Older Patients With Metastatic Pancreatic Cancer

Dr. O'Reilly on Nab-Paclitaxel Plus Gemcitabine Vs FOLFIRINOX

Improving Outcomes in Pancreatic Cancer With Perioperative mFOLFIRINOX

Targeted Oncology

GAP study: nab-paclitaxel & gemcitabine in locally advanced, unresectable pancreatic cancer

Advanced Pancreatic Cancer: Deciding Among Frontline Standards of Care

Debate: Optimal adjuvant chemotherapy for resected pancreatic cancer - Gemcitabine/capecitabine

Dose Modification Rationale in Advanced Pancreatic Cancer

Pancreatic cancer properties describe gemcitabine response

Journal of Clinical Investigation

Dr. Simeone on Benefit of Neoadjuvant Gemcitabine in Pancreatic Cancer